natgillin/translations-raw huggingface dataset:
Co-administration with Genvoya may result in increased plasma concentrations of salmeterol, which is associated with the potential for serious or life-threatening adverse reactions.
Sočasno dajanje z zdravilom Genvoya lahko povzroči zvišanje koncentracij salmeterola v plazmi, kar je povezano z možnimi resnimi ali življenjsko nevarnimi neželenimi učinki.
Co-administration with herbal preparations containing St John’s wort (Hypericum perforatum) (see section 4.5).
Sočasno jemanje z zdravili rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum) (glejte poglavje 4.5).
Co-administration with herbal preparations containing St. John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz (see section 4.5).
Sočasna uporaba s pripravki rastlinskega izvora, ki vsebujejo šentjanževko (Hypericum perforatum), ker obstaja tveganje za zmanjšanje koncentracije efavirenza v plazmi in zmanjšanje njegovega kliničnega učinka (glejte poglavje 4.5).
Co-administration with high dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose. (see section 4.5, for lower doses see section 4.4).
Sočasna uporaba z velikimi odmerki ritonavirja (400 mg in več, dvakrat na dan), ker ritonavir pri takšnih odmerkih pomembno zmanjša plazemsko koncentracijo vorikonazola pri zdravih preskušancih (glejte poglavje 4.5, za nižje odmerke glejte poglavje 4.4).
Co-administration with inducers of cytochrome P450 3A (CYP3A) or P-glycoprotein (P-gp), such as efavirenz, phenytoin, carbamazepine, bosentan, etravirine, modafinil or St. John’s wort (Hypericum perforatum).
Sočasna uporaba z induktorji citokroma P450 3A (CYP3A) ali P-glikoproteina (P-gp), kot so efavirenz, fenitoin, karbamazepin, bosentan, etravirin, modafinil ali šentjanževka (Hypericum perforatum).
Co-administration with inducers of metabolic enzymes
Sočasna uporaba z induktorji presnovnih encimov
Co-administration with inhibitors of organic anion transporting polypeptide 1B (OATP1B), such as rifampicin, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cobicistat or ciclosporin.
Sočasna uporaba z zaviralci transportnega polipeptida organskih anionov 1B (OATP1B), kot so rifampicin, atazanavir, darunavir, lopinavir, sakvinavir, tipranavir, kobicistat ali ciklosporin.
co-administration with itraconazole
očasnem dajanju z itrakonazolom
Co-administration with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured as area under the curve [AUC]) by 8.5-fold and increased hydroxymethyl-ivacaftor (M1) to a lesser extent than ivacaftor.
Sočasna uporaba s ketokonazolom, ki je močan zaviralec CYP3A, je zvečala izpostavljenost ivakaftorju (merjeno kot površino pod krivuljo [AUC]) za 8,5-krat in zvečala izpostavljenost hidroksimetil-ivakaftorju (M1) v manjši meri kot za ivakaftor.
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Sočasna uporaba z zdravili, ki so substrati izooblike CYP3A4 citokroma P450 in imajo ozko terapevtsko okno (npr. kvetiapin, alfuzosin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralne oblike midazolama (za previdnost pri parenteralnih oblikah midazolama glejte poglavje 4.5) in alkaloidi ergot, zlasti ergotamin, dihidroergotamin, ergonovin, metilergonovin) (glejte poglavje 4.5).
Co-administration with medicinal products that increase serum sodium concentration
Sočasno dajanje z zdravili, ki zvišujejo koncentracije natrija v serumu
Co-administration with medicinal products that induce 3A4 activity may reduce the efficacy of Instanyl.
Sočasna uporaba z zdravili, ki inducirajo aktivnost 3A4, lahko zmanjša učinkovitost zdravila Instanyl.
Co-administration with medicinal products that inhibit P-gp and/or BCRP may increase ledipasvir and sofosbuvir plasma concentrations without increasing GS-331007 plasma concentration; Harvoni may be co-administered with P-gp and/or BCRP inhibitors.
Sočasno dajanje z zdravili, ki zavirajo P-gp in/ali BCRP, lahko poveča koncentracijo ledipasvirja in sofosbuvirja v plazmi brez povečanja koncentracije GS-331007 v plazmi, zato se lahko zdravilo Harvonidaje sočasno z zaviralci P-gp in/ali BCRP.
Co-administration with medicinal products with narrow therapeutic windows and which are substrates of CYP3A4 [e.g., terfenadine, astemizole, cisapride, amiodarone, quinidine, pimozide, triazolam, orally administered midazolam (for caution on parenterally administered midazolam, see section 4.5), ergot derivatives, lovastatin and simvastatin, alfuzosin, and sildenafil when used for treatment of pulmonary arterial hypertension hypertension (for the use of sildenafil and other PDE-5 inhibitors in patients with erectile dysfunction, see section 4.5)].
Sočasno jemanje z zdravili, ki imajo ozko terapevtsko okno in ki so substrati za CYP3A4 [npr. terfenadin, astemizol, cisaprid, amiodaron, kvinidin, pimozid, triazolam, peroralno dan midazolam (za previdnost pri parenteralnih oblikah midazolama glejte poglavje 4.5), derivati ergot, lovastatin in simvastatin, alfuzosin in sildenafil, kadar se uporablja za zdravljenje pljučne arterijske hipertenzije (za uporabo sildenafila in drugih zaviralcev PDE-5 pri bolnikih z erektilno disfunkcijo glejte poglavje 4.5)].
Co-administration with medicinal products with narrow therapeutic windows and which are substrates of CYP3A4 [e.g., terfenadine, astemizole, cisapride, amiodarone, quinidine, pimozide, triazolam, orally administered midazolam (for caution on parenterally administered midazolam, see section 4.5), ergot derivatives, lovastatin and simvastatin, alfuzosin, and sildenafil when used for treatment of pulmonary arterial hypertension, (for the use of sildenafil and other PDE-5 inhibitors in patients with erectile dysfunction, see section 4.5)].
Sočasno jemanje z zdravili, ki imajo ozko terapevtsko okno in ki so substrati za CYP3A4 [npr. terfenadin, astemizol, cisaprid, amiodaron, kvinidin, pimozid, triazolam, peroralno dan midazolam (za previdnost pri parenteralnih oblikah midazolama glejte poglavje 4.5), derivati ergot, lovastatin in simvastatin, alfuzosin in sildenafil, kadar se uporablja za zdravljenje pljučne arterijske hipertenzije (za uporabo sildenafila in drugih zaviralcev PDE-5 pri bolnikih z erektilno disfunkcijo glejte poglavje 4.5)].
Co-administration with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine) (see section 4.5).
Sočasna uporaba zdravil, katerih očistek je zelo odvisen od CYP3A4/5 in pri katerih je zvišana koncentracija v plazmi povezana z resnimi in/ali življenjsko nevarnimi učinki; takšna zdravila so npr. peroralno uporabljeni midazolam in triazolam, bepridil, pimozid, lumefantrin, halofantrin, zaviralci tirozin-kinaze, simvastatin, lovastatin, kvetiapin, alfuzosin, silodozin in derivati ergot alkaloidov (dihidroergotamin, ergonovin, ergotamin, metilergonovin) (glejte poglavje 4.5).
Co-administration with midazolam may cause enhanced sedation or respiratory and cardiovascular depression.
Sočasno dajanje z midazolamom lahko okrepi učinek sedacije ali respiratorne in kardiovaskularne depresije.
Co-administration with midazolam may cause enhanced sedation or respiratory or cardiovascular depression.
Sočasno dajanje z midazolamom lahko okrepi učinek sedacije ali povzroči respiratorno ali kardiovaskularno depresijo.
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4).
Sočasna uporaba z blagimi induktorji CYP3A4/5, kot so aprepitant, prednizon in pioglitazon, lahko povzroči blago do zmerno zniţanje ravni izavukonazola v plazmi; sočasni uporabi blagih induktorjev CYP3A4/5 se je treba izogniti, razen če presodite, da morebitna korist odtehta tveganje (glejte poglavje 4.4).
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone, and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild
Sočasna uporaba z blagimi induktorji CYP3A4/5, kot so aprepitant, prednizon in pioglitazon, lahko povzroči blago do zmerno zniţanje ravni izavukonazola v plazmi; sočasni uporabi blagih induktorjev
Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone, and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.5).
Sočasna uporaba z blagimi induktorji CYP3A4/5, kot so aprepitant, prednizon in pioglitazon, lahko povzroči blago do zmerno zniţanje ravni izavukonazola v plazmi; sočasni uporabi blagih induktorjev CYP3A4/5 se je treba izogniti, razen če presodite, da morebitna korist odtehta tveganje (glejte poglavje 4.5).
Co-administration with other direct acting antivirals against HCV
Sočasno dajanje z drugimi zdravili proti HCV z neposrednim delovanjem na viruse
co-administration with other doses
drugimi odmerki
co-administration with other doses
drugimi odmerki atazanavirja ni
co-administration with other doses
odmerjanju pri sočasnem dajanju z
Co-administration with other HIV protease inhibitors (PIs)
(Lopinavir/ritonavir
Co-administration with other HIV protease inhibitors (PIs)
Sočasna uporaba z drugimi zaviralci proteaz HIV (PI)
Co-administration with other treatments for hyponatraemia and medicinal products that increase serum sodium concentration
Sočasno dajanje z drugimi oblikami zdravljenja hiponatriemije in zdravili, ki povečajo koncentracije natrija v serumu
Co-administration with potent cytochrome P 450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir (see section 4.5)
Sočasna uporaba z močnimi zaviralci citokroma P 450 (CYP) 3A4, npr. ketokonazolom, itrakonazolom, vorikonazolom, pozakonazolom, telitromicinom, klaritromicinom, nefazodonom ali ritonavirjem (glejte poglavje 4.5).
Co-administration with products containing St. John’s wort (Hypericum perforatum) (see section 4.5).
Sočasna uporaba z zdravili, ki vsebujejo šentjanževko (Hypericum perforatum) (glejte poglavje 4.5).
Co-administration with propranolol can cause altered automaticity (excessive bradycardia, sinus arrest), sino-atrial and atrio-ventricular conduction disorders, and increased risk of ventricular arrhythmias (torsades de pointes) along with heart failure.
Sočasna uporaba s propranololom lahko povzroči spremenjen avtomatizem (čezmerno bradikardijo, sinusni zastoj), motnje pri sinoatrijskem in atrioventrikularnem prevajanju in povečano tveganje ventrikularne aritmije (torsades de pointes) sočasno s srčnim popuščanjem.
Co-administration with REYATAZ/ritonavir may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Pri sočasni uporabi zdravila REYATAZ/ritonavirja se koncentracije salmeterola lahko povečajo in s tem se poveča tudi pojavnost neželenih učinkov salmeterola.
Co-administration with REYATAZ/ritonavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5- inhibitor-associated adverse events.
Pri sočasni uporabi zdravila REYATAZ/ritonavirja se koncentracije zaviralca PDE5 lahko povečajo in s tem se poveča tudi pojavnost neželenih učinkov zaviralca PDE5.
Co-administration with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index is not recommended (see section 4.5).
Sočasne uporabe z občutljivimi substrati CYP3A ali substrati CYP3A z majhnim terapevtskim oknom ne priporočajo (glejte poglavje 4.5).
Co-administration with Stribild may result in increased plasma concentrations of these drugs, which is associated with the potential for serious and/or life- threatening reactions.
Sočasno dajanje z zdravilom Stribild lahko povzroči zvišanje koncentracij teh zdravil v plazmi, kar je povezano z možnimi resnimi in/ali življenjsko nevarnimi reakcijami.
Co-administration with strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long- acting barbiturates (e.g. phenobarbital), phenytoin and St. John‟s wort or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine (see section 4.5).
Sočasna uporaba z močnimi induktorji CYP3A4/5, kot so rifampicin, rifabutin, karbamazepin, dolgodelujoči barbiturati (npr. fenobarbital), fenitoin in šentjanţevka, ali z zmernimi induktorji CYP3A4/5, kot so efavirenz, nafcilin in etravirin (glejte poglavje 4.5).
Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see sections 4.4 and 4.5).
Sočasna uporaba s substrati CYP3A4 terfenadinom, astemizolom, cisapridom, pimozidom, halofantrinom ali kinidinom, ker lahko povzroči povečanje plazemskih koncentracij teh zdravil, kar bi vodilo do podaljšanja intervala QTc, redko pa tudi do pojava torsades de pointes (glejte poglavji 4.4 in 4.5).
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening adverse reactions (see section 4.5):
Sočasna uporaba z naslednjimi zdravili zaradi možnega pojava resnih in/ali smrtno nevarnih neželenih učinkov (glejte poglavje 4.5):
Co-administration with the following medicinal products due to the potential for serious and/or life- threatening events or loss of therapeutic effect (see sections 4.4 and 4.5):
Sočasno dajanje z naslednjimi zdravili zaradi možnih resnih in/ali življenjsko nevarnih dogodkov ali izgube terapevtskega učinka (glejte poglavji 4.4 in 4.5):
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening events or loss of virologic response and possible resistance to Stribild (see section 4.5):
Sočasno dajanje z naslednjimi zdravili zaradi možnih resnih in/ali življenjsko nevarnih dogodkov ali izgube virološkega odziva in možne rezistence na zdravilo Stribild (glejte poglavje 4.5):
Co-administration with the following medicinal products due to the potential for serious or life-threatening adverse reactions or loss of virologic response and possible resistance to Genvoya (see section 4.5):
Sočasno dajanje z naslednjimi zdravili zaradi možnih resnih ali življenjsko nevarnih neželenih učinkov ali izgube virološkega odziva in možne rezistence na zdravilo Genvoya (glejte poglavje 4.5):
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics)
Sočasna uporaba z naslednjimi zdravili, ki so močni induktorji izooblike CYP3A4 citokroma P450, zaradi možne izgube terapevtskega učinka (glejte poglavje 4.5):
Co-administration with transport substrates/inhibitors
Sočasna uporaba s substrati/zaviralci prenašalcev
Co-administration with Tybost is not recommended.
Sočasno dajanje z zdravilom Tybost se ne priporoča.
Co-administration with warfarin (a CYP2C9 substrate)
Sočasna uporaba z varfarinom (substrat za CYP2C9)
Co-administration with warfarin (a CYP2C9 substrate)
Sočasna uporaba z varfarinom (substratom CYP2C9)
Co-administration with ZEPATIER is
Sočasna uporaba z zdravilom ZEPATIER je
Co-infected patients with advanced cirrhosis receiving combined anti-retroviral therapy (cART) may be at increased risk of hepatic decompensation and death.
Sočasno okuženi bolniki z napredovalo cirozo, ki prejemajo kombinirano protiretrovirusno terapijo (cART – combined anti-retroviral therapy), imajo lahko zvečano tveganje za nastanek jetrne dekompenzacije in smrti.
Co-infected patients with advanced cirrhosis receiving HAART may be at increased risk of hepatic decompensation and death.
Sočasno okuženi bolniki z napredovalo cirozo jeter, ki prejemajo HAART, imajo lahko večje tveganje za jetrno dekompenzacijo in smrt.
Co-infected patients with advanced cirrhosis receiving highly active anti-retroviral therapy (HAART) may be at increased risk of hepatic decompensation and death.
Sočasno okuženi bolniki z napredovalo cirozo, ki prejemajo visoko aktivno protiretrovirusno terapijo (HAART), imajo lahko povečano tveganje za nastanek jetrne dekompenzacije in smrt.
Co-infected patients with advanced cirrhosis receiving highly active anti-retroviral therapy (HAART) may be at increased risk of hepatic decompensation and death.
Sočasno okuženi bolniki z napredovalo cirozo, ki prejemajo visoko aktivno protivirusno terapijo (highly active anti-retroviral therapy - HAART), imajo lahko povečano tveganje za nastanek jetrne dekompenzacije in smrt.
Co-infected patients with advanced liver disease receiving (HAART) may be at increased risk of worsening liver function.
Sočasno okuženi bolniki z napredovalo jetrno boleznijo, ki prejemajo močno aktivno protiretrovirusno terapijo (HAART), imajo lahko povečano tveganje za pojav poslabšane jetrne funkcije.
Co-infected patients with advanced liver disease receiving HAART may be at increased risk of worsening liver function.
sočasno okuženi bolniki z napredovalo jetrno boleznijo, ki prejemajo močno aktivno protiretrovirusno terapijo (HAART), imajo lahko povečano tveganje za pojav poslabšane jetrne funkcije.
co-infection
okužba s
co-infection
okužbo s
Co-infection with HBV (hepatitis B virus) or HCV (hepatitis C virus)
Sočasna okužba z virusom hepatitisa B (HBV) ali C (HCV)
Co-infection with Hepatitis B or C
Sočasna okužba z virusom hepatitisa B ali C
Co-infection with HIV-1 and hepatitis B: Due to the risk of development of HIV resistance, tenofovir disoproxil fumarate should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients.
Sočasna okužba z virusom HIV-1 in virusom hepatitisa B: Zaradi tveganja za nastanek odpornosti virusa HIV se sme dizoproksiltenofovirijev fumarat pri bolnikih, okuženih z virusoma HIV/HBV, uporabljati samo kot del ustreznega režima kombiniranega protiretrovirusnega zdravljenja.
Co-medication of drugs increasing the upper gastro intestinal pH may lead to lower oral bioavailability.
Sočasna uporaba zdravil, ki zvišujejo pH vrednost v zgornjih prebavilih, lahko povzroči manjšo peroralno biološko uporabnost.
Co-medication with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)
Sočasno zdravljenje s selektivnimi zaviralci ponovnega privzema serotonina (SSRI) ali selektivnimi zaviralci ponovnega privzema serotonina in noradrenalina (SNRI)
Co-morbidity 0 or 1 (n=126)
Komorbidnost 0 ali 1 (n = 126)
Co-morbidity 2 or more (n=321)
Komorbidnost 2 ali več (n = 321)
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rPFS).
Dodatni primarni cilji opazovanja so bili celokupno preživetje in radiografsko potrjeno preživetje brez napredovanja bolezni (rPFS – radiographic progression-free survival).
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rPFS).
Sočasna primarna opazovana dogodka učinkovitosti sta bila celokupno preživetje in radiografsko preživetje brez napredovanja bolezni (rPFS - radiographic progression-free survival).
Co-primary endpoints: ARR & SAD.
Sočasni primarni končni točki: ARR in SAD.
Co-treatment with other drugs that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic drug interactions.
Sočasno zdravljenje s pripravki, ki so substrati/inhibitorji P- glikoproteinov (npr. ivermektin in drugi protiparazitarni makrociklični laktoni, eritromicin, prednizolon in ciklosporin), lahko povzroči farmakokinetične interakcije.
Co-treatment with other drugs that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic drug interactions.
Sočasno zdravljenje z zdravili, ki so substrati/inhibitorji P- glikoproteinov (npr. ivermektin in drugi protiparazitarni makrociklični laktoni, eritromicin, prednizolon in ciklosporin) lahko povzroči farmakokinetične interakcije.
Co-treatment with other veterinary medicinal products that are P-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic interactions.
Sočasno zdravljenje z drugimi zdravili za uporabo v veterinarski medicini, ki so substrati/inhibitorji P-glikoproteinov (npr. ivermektin in drugi protiparazitarni makrociklični laktoni, eritromicin, prednizolon in ciklosporin), lahko povzroči farmakokinetične interakcije.
Co. Down United Kingdom
Newry Co.
Co. Down, BT35 6PU
Co Down, BT35 6PU
Co. Durham DL12 8DT United Kingdom
Durham DL12 8DT Velika Britanija
Co. Durham DL12 8DT United Kingdom
Velika Britanija
Co. Galway Ireland
Galway, Irska.
Co. Galway, IRELAND
Galway, IRSKA.
Co. Galway, Ireland.
Galway, Irska.
Co. Kerry, Ireland
County Kerry, Irska
coadminister atazanavir/ritonavir and Nevirapine Teva (see section 4.4).
Sočasno dajanja atazanavirja z ritonavirjem in zdravila Nevirapin Teva ni priporočeno (glejte poglavje 4.4).
coadministered with
ANTIHIPERLIPEMIKI
coadministered without dose adjustments.
Viramune in abakavir lahko dajemo sočasno brez prilagoditve odmerkov.
coadministration
ketokonazol
coadministration
merjena.
Coadministration of
Sočasna uporaba vorikonazola
Coadministration of a single 150 mg oral dose of crizotinib in the presence of ketoconazole (200 mg twice daily), a strong CYP3A inhibitor, resulted in increases in crizotinib systemic exposure, with crizotinib area-under-the-plasma-concentration versus time curve from time zero to infinity (AUCinf) and maximum observed plasma concentration (Cmax) values that were approximately 3.2-fold and 1.4-fold, respectively, those seen when crizotinib was administered alone.
Sočasna uporaba enkratnega 150 mg peroralnega odmerka krizotiniba v prisotnosti ketokonazola, močnega zaviralca CYP3A (200 mg dvakrat na dan), je povzročila povečanje sistemske izpostavljenosti krizotinibu, z vrednostmi površine pod krivuljo plazemske koncentracije v odvisnosti od časa, od časa nič do neskončnosti (AUCinf), in največje opažene plazemske koncentracije (Cmax) za krizotinib, ki so bile za približno 3,2-krat oziroma 1,4-krat večje od tistih, ki so jih beležili ob uporabi krizotiniba samega.
Coadministration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.4), e.g. if antagonistic effects can be expected.
Sočasnemu jemanju antipsihotičnih zdravil in pramipeksola se je treba izogibati (glejte poglavje 4.4), npr. kadar je pričakovan antagonistični učinek.
Coadministration of crizotinib with strong CYP3A inhibitors may increase crizotinib plasma concentrations.
Sočasno jemanje krizotiniba skupaj z močnimi zaviralci CYP3A lahko poveča plazemske koncentracije krizotiniba.